Anupam Rasayan India Ltd.
NSE: ANURASAnupam Rasayan India Ltd.: A 30-second snapshot
Anupam Rasayan (ANURAS) trades at ₹1,210.8, down 14.43% from its 52-week high and 10.92% over the past 3 months, currently below both its 50-DMA (₹1,281.72) and 200-DMA (₹1,261.02) with RSI at 26.95 (oversold). Five-year revenue growth of 27.5% has been accompanied by a 5-year earnings CAGR of -7.6%, ROE of 5.76%, and free cash flow positive in only 1 of the available years, while the trailing PE of 78.53 is the second-highest and the quality score of 13 the lowest among 6 ranked Chemicals sector peers. Recent news flow centers on a $300 million LOI with BASQUEVOLT for battery chemicals and an ₹829 crore open offer for a 26% stake in Bliss GVS Pharma.
P/E
78.5
Forward P/E
36.9
ROE
+5.8%
Debt / Equity
41.32
Profit Margin
+7.2%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
1/5
Quality
31/100
News
6 headlines · 6 positive · 0 negative
Anupam Rasayan Opens ₹829 Crore Open Offer for Bliss GVS Pharma - whalesbook.com
whalesbook.com
Anupam Rasayan Signs $300 Million Battery Chemical Deal - whalesbook.com
whalesbook.com
Anupam Rasayan Signs $300 Million LOI With BASQUEVOLT; Shares Slip - HDFC Sky
HDFC Sky
Anupam Rasayan: Bliss GVS Pharma-வில் 26% பங்குகளை வாங்க அதிரடி ஆஃபர்! - whalesbook.com
whalesbook.com
Anupam Rasayan ਦਾ ₹829 ਕਰੋੜ ਦਾ ਓਪਨ ਆਫਰ: Bliss GVS Pharma ਦੇ 26% ਸ਼ੇਅਰ ਖਰੀਦੇਗੀ ਕੰਪਨੀ - whalesbook.com
whalesbook.com
Recent context
- ·On 2026-07-15, Anupam Rasayan signed a $300 million LOI with BASQUEVOLT for battery chemicals; one report on the same announcement was headlined 'Shares Slip.'
- ·On 2026-07-21, the company opened an ₹829 crore open offer to acquire a 26% stake in Bliss GVS Pharma.
- ·All 6 retrieved headlines are labeled positive sentiment but trace back to just these 2 underlying events (duplicated across sources and languages), over a period in which the stock fell 10.92% on a 3-month basis.
Strengths
- +5-year revenue CAGR of 27.5%, one of the stronger growth metrics in the available dataset.
- +Forward PE of 36.94 is roughly half the trailing PE of 78.53, reflecting current analyst EPS estimates for the year ahead.
- +Current price of ₹1,210.8 sits just 0.2% above the nearest identified support level (₹1,208.2), with RSI at 26.95 in oversold territory.
- +Two corporate-development announcements in the past three weeks: a $300 million LOI with BASQUEVOLT for battery chemicals (2026-07-15) and an ₹829 crore open offer for a 26% stake in Bliss GVS Pharma (2026-07-21).
Weaknesses
- −Free cash flow was positive in only 1 of the available historical years, ROE is 5.76% with 0 years above 15%, and 5-year earnings CAGR is -7.6% despite 27.5% revenue CAGR, with the debt trend classified as rising.
- −Quality score of 13 is the lowest among the 6 ranked Chemicals sector peers (PIDILITIND 66, SOLARINDS 61, SRF 56, COROMANDEL 30, PIIND 23).
- −Trailing PE of 78.53 is the second-highest among the 6 ranked peers, behind only SOLARINDS at 98.90, despite carrying the lowest quality score in the group.
- −Price is below both the 50-DMA (₹1,281.72) and 200-DMA (₹1,261.02), down 10.92% over 3 months and 14.43% below its 52-week high.
Open questions
- ?Does the ₹829 crore cash outlay for a 26% stake in Bliss GVS Pharma affect the company's rising debt trend, given FCF was positive in only 1 of the available years?
- ?What explains the gap between 27.5% 5-year revenue growth and -7.6% 5-year earnings growth — margin compression, one-off costs, or scale-up expenses tied to new lines like battery chemicals?
- ?How does a quality score of 13 (lowest of 6 ranked Chemicals peers) reconcile with a trailing PE of 78.53 that is the second-highest in the same peer set?
- ?Is the current RSI of 26.95 and price position near the ₹1,208.2 support level tied to company-specific developments, or to broader sector and market conditions?
Peer comparison: Chemicals
Ranks 6 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ANURAS | Anupam Rasayan India Ltd.You're viewing | 78.5 | +5.8% | 13 |
| Industry avg | across 5 peers | 53.4 | +22.4% | 47 |
| PIDILITIND | Pidilite Industries Ltd. | 67.3 | +23.5% | 66 |
| SOLARINDS | Solar Industries India Ltd. | 98.9 | +31.2% | 61 |
| SRF | SRF Ltd. | 36.0 | — | 56 |
| COROMANDEL | Coromandel International Ltd. | 33.4 | — | 30 |
| PIIND | PI Industries Ltd. | 31.6 | +12.3% | 23 |
Technical state
Current price
₹1,210.80
SMA 50
₹1,281.72
SMA 200
₹1,261.02
RSI (14)
26.9 (oversold)
From 52w high
-14.4%
1Y return
+5.7%
3M return
-10.9%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highFree cash flow was positive in only 1 of the available historical years and the debt trend is classified as rising; ROE is 5.76% with 0 of the available years above 15%, and 5-year earnings CAGR is -7.6% despite 5-year revenue CAGR of +27.5% — revenue growth has not converted into profitability or cash generation.
- mediumQuality score of 13 is the lowest among the 6 ranked Chemicals sector peers in this dataset (PIDILITIND 66, SOLARINDS 61, SRF 56, COROMANDEL 30, PIIND 23).
- mediumTrailing PE of 78.53 (forward PE 36.94) is the second-highest among the 6 ranked sector peers, behind only SOLARINDS at 98.90, despite ANURAS carrying the lowest quality score in that same peer group.
- lowPrice of ₹1,210.8 is below both the 50-DMA (₹1,281.72) and 200-DMA (₹1,261.02), down 10.92% over 3 months and 14.43% below its 52-week high, with RSI at 26.95 (oversold); priceChange1Y remains positive at +5.73%.
- lowAnalyst rating is unavailable despite 6 analysts tracked, and 1-year price-change data is missing for all 5 listed sector peers, which precludes a relative price-momentum comparison.
Cross-section contradictions
- 5-year revenue CAGR of +27.5% did not translate into earnings growth (5-year earnings CAGR of -7.6%) or capital efficiency (ROE 5.76%, 0 years above 15%, FCF positive in only 1 available year) — top-line growth without a matching profitability or cash-conversion trend.
- All 6 retrieved news items are classified positive sentiment — including one whose own headline reads 'Shares Slip' on the BASQUEVOLT LOI announcement — yet the stock is down 10.92% over 3 months and trades below both its 50-DMA and 200-DMA.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 12 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days